RNATE
LIVE

Serial Number

97347615

Owner

Seqirus Inc.

Attorney

Nancy Sabarra

Filing Date

Apr 5, 2022

Add to watchlist:

No watchlists yet
View on USPTO

RNATE Trademark

Serial Number: 97347615

RNATE is a trademark filed by Seqirus Inc. on April 5, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Seqirus Inc. (84 trademarks)

475 Green Oaks Parkway
Holly Springs, NC 27540

Entity Type: 03

Trademark Details

Filing Date

April 5, 2022

Registration Date

Not Registered

Published for Opposition

May 9, 2023

Goods & Services

Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells

Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines

Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use

Medical services; medical information; providing a website featuring medical information

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 29, 2026 EXRA
SOU EXTENSION 5 GRANTED
May 29, 2026 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 28, 2026 AITU
SOU TEAS EXTENSION RECEIVED
Jan 5, 2026 EEXT
SOU EXTENSION 5 FILED
Jan 4, 2026 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 27, 2025 EXRA
SOU EXTENSION 4 GRANTED
Jun 26, 2025 EX4G
SOU EXTENSION 4 FILED
Jun 26, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 26, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jan 3, 2025 EX3G
SOU EXTENSION 3 FILED
Jan 2, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jan 2, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 2 GRANTED
Jun 6, 2024 EX2G
SOU EXTENSION 2 FILED
Jun 6, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 6, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Dec 19, 2023 EX1G
SOU EXTENSION 1 FILED
Dec 19, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 19, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 4, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 9, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 9, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 19, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 5, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 5, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 5, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 5, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 5, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 21, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 21, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jan 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jan 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jan 23, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 11, 2022 NWOS
NEW APPLICATION ENTERED
Apr 8, 2022 NWAP